Episode
Making Biologics Orally Available With Vivtex's Thomas von Erlach, Ph.D.
- Podcast
- Business Of Biotech
- Published
- Mar 2, 2026
- Duration seconds
- 3237
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/making-biologics-orally-available-with-vivtex-s-thomas-von-erlach-ph-d/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-of-biotech-123501/making-biologics-orally-available-with-vivtex-s-thomas-von-erlach-ph-d.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Thomas von Erlach, Ph.D., Cofounder and CEO at Vivtex, a company spun out of the Langer Lab at MIT that's focused on developing orally available biologics. The company announced a deal in late February '26 with Novo Nordisk for up to $2.1 billion to develop next-gen oral drugs for obesity and diabetes, bringing the total number of Vivtex's partnerships to 10. Thomas s...